Tirzepatide, Dulaglutide: Patient Voices

Seventy-four people who had spent years taking either tirzepatide or dulaglutide for type 2 diabetes sat down for one-on-one exit interviews after finishing the SURPASS-CVOT trial. The result leans strongly positive: 93.2% said they would be likely or very likely to recommend their treatment to someone else^[1]. This is qualitative research, meaning it asked people to describe their own experience in their own words instead of measuring a lab value, and it does not rank one drug against the other on effectiveness. Here is what patients actually said, and what the study can and cannot tell readers.

What the exit interviews looked like

SURPASS-CVOT is a large cardiovascular-outcomes trial, meaning it was built to track heart attacks, strokes and cardiovascular deaths, not just blood sugar. It enrolled 13,299 adults with type 2 diabetes and randomly assigned each person to weekly injectable tirzepatide or weekly injectable dulaglutide, sold as Trulicity^[2]. The exit interviews are a smaller sub-study nested inside that trial. Researchers invited 147 participants across 10 US sites who had recently finished their assigned treatment. Seventy-four agreed to a structured interview: 31 had taken dulaglutide and 43 had taken tirzepatide^[1]. Interviewers asked open-ended questions about what changed, what was hard, and whether the person would choose the treatment again, then grouped the answers into recurring themes. They did not run a statistical test comparing the two drug arms.

Worth knowing going in: SURPASS-CVOT is sponsored by Eli Lilly, which manufactures both tirzepatide (sold as Mounjaro and Zepbound) and dulaglutide (sold as Trulicity)^[2]. That funding relationship does not make the patient-reported findings inaccurate. The numbers reported are simple counts of what participants said, not a model that could be tuned to favor one arm. But a company studying satisfaction with its own two products has an obvious interest in both looking good, and a one-time interview design cannot fully rule out participants answering more favorably than they might on an anonymous form.

What patients said helped

The benefits participants reported most often clustered tightly. 97.3% described improved blood sugar control and 91.9% described weight loss as something they noticed and valued^[1]. Many also mentioned reduced appetite, an easier time sticking to a healthier diet, more day-to-day energy, and fewer cravings for foods they were trying to cut back on. A smaller number described benefits they had not expected going in, including improvement in joint pain or in sleep apnea symptoms^[1]. The published results do not break these figures out separately by drug, so this study alone cannot say whether tirzepatide patients or dulaglutide patients reported blood sugar improvement at different rates.

What patients said was hardest

Nausea was the single most frequently mentioned downside, reported by 28.4% of the people interviewed^[1]. That lines up with both drugs' US prescribing labels. Tirzepatide's label lists nausea, diarrhea, vomiting and constipation among the most common adverse reactions^[3], and dulaglutide's label lists nausea, diarrhea, vomiting, abdominal pain and decreased appetite at comparable frequency^[4]. Gastrointestinal side effects are the expected trade-off with this drug class: GLP-1 receptor agonists work partly by slowing how fast food leaves the stomach, and tirzepatide adds a second gut-hormone receptor, called GIP, on top of that mechanism. The exit interviews mostly confirm what the trial safety data already showed. They do not surface a new safety signal.

Would they do it again

Asked directly whether they would recommend their treatment, 77.0% said very likely and another 16.2% said likely, for a combined 93.2%^[1]. That is a high recommendation rate from people who had just spent months managing a weekly injection and, for more than a quarter of them, ongoing nausea. It suggests the benefits people described, better blood sugar control, weight loss, and more energy, outweighed the side effects for most of the group.

What this means

It is tempting to read a study naming both tirzepatide and dulaglutide as a verdict on which drug is better. This one is not that. The exit interviews report how satisfied people were with whichever drug they happened to be assigned. They are not a statistical comparison of tirzepatide against dulaglutide on any outcome, including blood sugar control, weight loss, or side-effect rates. SURPASS-CVOT's actual head-to-head evidence, the cardiovascular-event data the trial exists to generate, is a separate readout that had not published as of this writing^[2]. Anyone deciding between the two drugs on cardiovascular grounds should wait for that primary result, not this qualitative sub-study, and should talk it through with a clinician who knows their history.

What we don't yet know

A few limits are worth naming plainly. Only half of the people invited, 74 of 147, agreed to be interviewed, so the sample may skew toward people willing to talk about a positive experience^[1]. All 10 sites were in the United States, so the findings may not generalize to patients in other health systems. And because each interview happened once, after treatment ended, it relies on memory of months or years of treatment rather than a running log kept during the trial. None of that erases what patients said. It means their reported experience, not a controlled comparison between the two drugs, is what this study actually measured.